Ko-Med Centra Kliniczne Sp. z o.o.

The Ko‑Med Centra Kliniczne site conducts research aimed at reducing heart‑related events and improving blood‑vessel health in adults at elevated risk.

• Evaluating the novel anticoagulant asundexian for stroke and systemic embolism prevention in atrial fibrillation
• Assessing the impact of the lipid‑lowering antibody evolocumab on coronary death, myocardial infarction and ischemic stroke
• Long‑term safety and efficacy study of the APOC3 inhibitor ARO‑APOC3 in mixed dyslipidemia
• Risk‑reduction strategies for patients with high cardiovascular risk but no prior myocardial infarction or stroke

With five active trials and a team of 24 investigators, the Pulawy centre is a hub for advancing cardiovascular therapeutics across Europe.

Research at this facility focuses on metabolic imbalances, particularly abnormalities in blood lipids that increase cardiovascular danger.

• Investigation of APOC3 inhibition using ARO‑APOC3 to improve lipid profiles in adults with mixed dyslipidemia
• Evaluation of optimized lipid‑lowering regimens combined with novel agents for high‑risk patients
• Studies on metabolic risk factors that contribute to atherosclerotic disease
• Assessment of safety and long‑term outcomes of metabolic therapies in a real‑world population

The centre’s multidisciplinary team applies its expertise to develop better treatments for metabolic disorders, supporting both patients and clinicians.

This site is engaged in advancing care for inflammatory skin conditions, with a particular emphasis on moderate psoriasis.

• Dose‑selection study of the oral agent HRO350 for mild‑to‑moderate psoriasis
• Safety monitoring of new systemic therapies in adult patients with skin disease
• Comparative effectiveness research to identify optimal treatment regimens for psoriasis
• Exploration of patient‑reported outcomes to improve quality of life in dermatologic care

By integrating clinical evaluation with patient feedback, the Pulawy centre contributes to more personalized dermatology solutions.

The clinic investigates vaccine strategies to protect older adults from respiratory viral infections and related bacterial complications.

• Immune‑response assessment of the RSV investigational vaccine RSVPreF3 OA in seniors
• Co‑administration study of RSVPreF3 OA with the 20‑valent pneumococcal conjugate vaccine PCV20
• Safety and reactogenicity monitoring of combined viral‑bacterial vaccination in adults aged 60+
• Evaluation of neutralizing antibody levels against RSV‑A and RSV‑B subtypes

These vaccine trials aim to enhance protection against respiratory syncytial virus and pneumococcal disease, reflecting the site’s commitment to public‑health‑focused research.